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Abstract
Wepresent an integrative genome-wide analysis that can be used to predict the risk of progression from leukoplakia to oral
squamouscell carcinoma (OSCC) arising in thegingivobuccal complex (GBC).We find that thegenomic and transcriptomic
profiles of leukoplakia resemble those observed in later stages of OSCC and that several changes are associated with this
progression, including amplification of 8q24.3, deletion of 8p23.2, and dysregulation of DERL3, EIF5A2, ECT2, HOXC9,
HOXC13, MAL, MFAP5 and NELL2. Comparing copy number profiles of primary tumors with and without lymph-node
metastasis, we identify alterations associated with metastasis, including amplifications of 3p26.3, 8q24.21, 11q22.1,
11q22.3 and deletion of 8p23.2. Integrative analysis reveals several biomarkers that have never or rarely been reported in
previousOSCCstudies, includingamplificationsof1p36.33 (attributable toMXRA8), 3q26.31 (EIF5A2), 9p24.1 (CD274), and
12q13.2 (HOXC9 and HOXC13). Additionally, we find that amplifications of 1p36.33 and 11q22.1 are strongly correlated
withpoor clinical outcome.Overall, our findingsdelineategenomic changes that canbeused in treatmentmanagement for
patients with potentially malignant leukoplakia and OSCC patients with higher risk of lymph-node metastasis.
Translational Oncology (2017) 10, 396–409
Introduction
Oral cancer starts with an oral pre-invasive lesion (OPL) that
progresses from hyperplasia through dysplasia, and finally develops
into invasive oral squamous cell carcinoma (OSCC). Leukoplakia is
the most predominant pre-invasive lesion [1–4], however the ability
to predict the malignant potential from histopathological data is
limited. Moreover, the 5-year overall survival in OSCC has not
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substantially improved in recent decades [5], and early diagnosis and
primary prevention remain the best approaches for OSCC manage-
ment. To this end, the major challenge in early diagnosis is identifying
pre-invasive lesions that are at high risk of malignant transformation
[6,7]. However, OSCC is frequently diagnosed in advanced stages,
which negatively influences prognosis. The most important prognostic
factors that determine mortality and morbidity in OSCC patients are
lymph node involvement and locoregional recurrence.
The histopathological evaluation of oral cancers is often not
sufficient to predict disease aggressiveness and clinical outcome [8].
Multiple genetic and epigenetic events occur before tissue changes
are microscopically detectable. The number of acquired genetic
alterations increases with disease advancement from squamous
hyperplasia through dysplasia to invasive carcinoma [5]. It is
known that copy number alterations (CNAs) ranging from a small
number of specific genes to entire chromosomes are significantly
associated with OSCC development and progression [9,10]. These
alterations are presumed to alter the expression level of single genes
or gene clusters mapping within CNA regions [11]. Therefore,
analyses that integrate CNA data with gene expression (GE) data
may identify predictive DNA-based markers applicable in clinical
prognosis [12].
Molecular profiles of oral cancers are largely influenced by the site of
tumor development and associated etiological agents, implying
divergent pathways for oral cancer development [13–17]. India is an
interesting location to study the genomics of tobacco-associatedOSCC,
due to the fact that in India there is a high incidence of oral cancers
associated with the abuse of smokeless tobacco, most of which are
negative for human papilloma virus (HPV) [18].
This is the first comprehensive study combining genomic profiling
and integrative analyses of HPV-negative gingivobuccal complex (GBC)
leukoplakia and OSCC of different stages from a large set of Indian
patients. We identified signatures associated with the progression of
pre-invasive lesions to invasive OSCC and found candidate driver
alterations unique to primary tumors with lymph node metastasis and
related to patient survival.
Materials and Methods
Tissue Specimen Collection
The study was approved by the Institutional Local Ethics Committee
of Tata Memorial Hospital (TMH) and Nair Hospital Dental College,
Mumbai, India. Written informed consent was obtained from all the
study participants. Paraffin blocks and frozen tissue samples of
leukoplakia, neo-primary oral tumor tissues, and non-inflamed
gingivobuccal mucosa tissues from clinically healthy individuals with
no previous personal history of cancer were recruited fromNairHospital
and TMH, respectively. Patients received neither radiation nor
chemotherapy before surgery. Histopathologically confirmed leukopla-
kia and tumor tissues were subjected to DNA–RNA extraction as
detailed in Supplementary Information. Screening for the presence
of HPV was done as described in [18]. Details regarding the numbers
of samples used in the test and validation sets, as well as the
Table 1. The Clinicopathologic and Demographic Characteristic of the Study Patients.
Patient Characteristics Total Study Samples aCGH & GE Study (n = 121)# qRT-PCR (n = 207)# IHC & FISH (n = 370)#
Normal, Leukoplakia and OSCC Leukoplakia OSCC Leukoplakia OSCC Leukoplakia OSCC
n = 481 aCGH: n = 24 GE: n = 15 aCGH: n = 91 GE: n = 61 n = 37 n = 138 n = 108 n = 185
Age at diagnosis
Median age 49 42 50 41 50 44 50
Range (IQR)* 40–59 38–50 43–61 33–53 42–59 32–57 42–60
Gender
Male 299 (76.3%) 21 (87.5%) 70 (76.9%) 33 (89.2%) 102 (75.6%) 96 (90.6%) 140 (75.7%)
Female 93 (23.7%) 3 (12.5%) 21 (23.1%) 4 (10.8%) 33 (24.4%) 10 (9.4%) 45 (24.3%)
Pathological stage
Stage 1 and 2 (Early stage OSCC) 82 (35.5%) NA 32 (35.2%) NA 56 (41.5%) NA 67 (36.2%)
Stage 3 and 4 (Advanced stage OSCC) 149 (64.5%) NA 59 (64.8%) NA 79 (58.5%) NA 118 (63.8%)
Pathological T classification
T1 31 (13.4%) NA 7 (7.7%) NA 25 (18.5%) NA 24 (13%)
T2 100 (43.3%) NA 40 (44%) NA 64 (47.4%) NA 80 (43.2%)
T3 10 (4.3%) NA 4 (4.4%) NA 4 (3%) NA 8 (4.3%)
T4 90 (39%) NA 40 (44%) NA 42 (31.1%) NA 73 (39.5%)
Pathological cervical lymph node involvement
Node negative (N0) 133 (57.6%) NA 55 (60.4%) NA 79 (58.5%) NA 112 (60.5%)
Node positive (N+) 98 (42.4%) NA 36 (39.6%) NA 56 (41.5%) NA 73 (39.5%)
Pathological grade
Well 27 (7.9%) NA 8 (8.8%) NA 12 (8.9%) NA 23 (12.5%)
Moderate 139 (40.9%) NA 55 (60.4%) NA 87 (64.4%) NA 106 (57.6%)
Poor 64 (18.8%) NA 28 (30.8%) NA 36 (26.7%) NA 55 (29.9%)
Hyperplasia 89 (26.2%) 21 (87.5%) NA 31 (86.1%) NA 80 (80.8%) NA
Mild dysplasia 11 (3.2%) 3 (12.5%) NA 3 (8.3%) NA 9 (9.1%) NA
Moderate dysplasia 8 (2.4%) NA NA 2 (5.6%) NA 8 (8.1%) NA
Severe Dysplasia 2 (0.6%) NA NA NA NA 2 (2%) NA
Habit profile
No Habit 9 (3.1%) 9 (45%) NA NA 3 (2.6%) NA 8 (5.3%)
Exclusive tobacco users 157 (54.5%) 3 (15%) 63 (77.8%) 13 (41.9%) 79 (70%) 30 (33%) 98 (64.5%)
Exclusive smoker 18 (6.3%) NA 2 (2.5%) 5 (16.2%) 2 (2%) 12 (13.2%) 4 (2.6%)
Exclusive alcohol drinker 1 (0.3%) NA NA NA 1 (0.8%) NA 1 (0.7%)
Mixed habit** 103 (35.8%) 8 (40%) 16 (19.8%) 13 (41.9%) 28 (24.7%) 49 (53.8%) 41 (27%)
#Represents total number of samples, includingBuccalMucosa (BM)Normals: n = 6 (GE), n = 32 (qRT-PCR) andn = 77 (IHC); all samples belonged to the gingivobuccal complex region of the oral cavity; T:Tumor
classification based on size; N: Tumor classification based on lymph node metastasis; * IQR: Inter quartile range; **Mixed Habit: Tobacco chewing along with bidi/cigarette smoking and/or alcohol users.
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clinicopathologic and demographic characteristics of patients, are
provided in Table 1 and Figure S1.
Array CGH and Gene Expression Profiling
Whole-genome copy number and gene expression profiling was
performed on 2x105K CGH oligonucleotide arrays and Whole Human
Genome Microarray 4x44K (Agilent Technologies, USA) respectively.
Hybridization and detailed analysis are described in Supplementary
Information. The raw aCGH data have been submitted to the
Gene Expression Omnibus (GEO) with accession numbers GSE85514
and GSE23831 and accession numbers for GE raw data are GSE85195
and GSE23558.
Validation of Targets
The copy number status of the targets was evaluated by
fluorescence in situ hybridization (FISH/nuc ish). Immunohisto-
chemical analysis (IHC) and quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) were performed for selected
candidate genes found significantly deregulated. Detailed protocol
and analysis is provided in Supplementary Information. Details
regarding FISH probes, fluorescent TaqMan probes and antibodies
used are listed in Tables S1, S2, S3.
Literature Mining
We updated our existing literature-based list of genes related to
oral cancer from 277 genes [10] to 562 genes (as of May 2015).
The list (Table S4) includes genes that were previously found to be
either differentially expressed or copy number altered in oral
cancers. The purposes were 1) to place our new results in the
context of previous knowledge and 2) to determine the novelty of
any gene expression change or CNA that we would choose for
targeted validation.
Figure 1. All amplifications (a) and deletions (b) inferred by GISTIC 2.0 in leukoplakia (A), early-stage OSCC (B), and advanced-stage OSCC
(C) samples. Each alteration is assigned a G-score (left axis) by GISTIC 2.0, which considers the amplitude of the alteration, as well as its
occurrence across samples.
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Figure 2. Nuc ish (FISH) for validating the amplifications of the regions 8q24.3 and 1p36.33. A) nuc ish for 8q24.3 locus in leukoplakia (b)
and OSCC (c). B) nuc ish for 1p36.33 locus with weak amplification (b) and strong amplification (c) in OSCC. The specificities of the 8q24.3
locus probe (red)/chr 8 centromere (CEP) (green) and 1p36.33 (red) locus probe/chr 1 centromere (CEP) (green) were confirmed on the
metaphase spreads as represented in A(a) and B(a). In all cases, the magnification was 630X.
Figure 3. Correlation between 8q24.3 amplification and oral cancer progression. A) Percentage of cells with 8q24.3 weak amplification
across different groups, correlated with disease progression (P-value calculated using Spearman correlation). B) and C) The increased
percentage of tumor cells with 8q24.3 amplification in leukoplakia and OSCC.
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Results
Clinicopathological and Demographic Characteristics of the
Study Cohort
Clinicopathological and demographic characteristics of all 481
leukoplakia and OSCC patients, together with follow-up data, are
summarized in Tables 1 and S5, while Figure S1 shows how many
samples were used in each phase of the study. Most patients were
smokeless tobacco users while many had mixed habits (~35%)
(chewing, bidi/cigarette smoking or consuming alcohol) and were
negative for high-risk HPV [18]. The histopathology of the leukoplakia
samples was either hyperplastic (89 samples) or mild dysplastic (11
samples) and 50% of the lesions analyzed for aCGH and GE study
either transformed to OSCC or recurred after primary treatment. One
hundred forty-nine patients (~65%) had advanced-stage OSCC and 82
patients (~35%) had early-stage OSCC. Approximately 60% cases were
negative for lymph node metastasis.
Genome-Wide copy Number Alterations
Genome-wide analysis of CNA was carried out in 24 leukoplakia,
32 early-stage OSCC, and 59 advanced-stage OSCC cases and revealed
recurrent focal regions of amplification and deletion (Figures 1
and S2). We identified 19 alterations in leukoplakia, 32 alterations in
early-stage OSCCs and 69 alterations in advanced-stage OSCCs (Table
S6). The 10most frequently amplified regions were 11q13.1 (70%of all
patients), 8q24.3 (69%), 11p15.5 (60%), 1p36.33 (59%), 9q34.3
(59%), 8q24.21 (55%), 7q22.1 (54%), 7q11.23 (53%), 16p13.3
(53%) and 3q27.2 (52%). The 10most frequently deleted regions were
8p23.2 (66% of all patients), 8p11.22 (65%), 3p14.2 (56%), 3p21.1
(54%), 8p22 (54%), 3p11.1 (53%), 3p22.3 (53%), 3p26.3 (53%),
8p23.1 (51%) and 15q11.1 (40%). Previous reports have proposed
amplifications in 3q26-qter, 8q24-qter, and 11q13.2-q13.4 to be
common in high grade dysplasia, and amplifications in 3q, 7p, 8q,
11q, together with deletions in 3p and 8p to be most common in
OSCCs [19].
CNAs associated with disease progression. Alterations associated
with disease progression were identified by comparison between the
following groups: 1) leukoplakia vs. early-stage OSCC, 2) leukoplakia
vs. advanced-stage OSCC, and 3) early-stage OSCC vs. advanced-
stage OSCC (Figure S2). Three amplified regions (4q13.2, 6p21.32,
8q24.3) and four deleted regions (8p23.1, 8p11.22, 14q11.2,
15q11.1) are common among the leukoplakia, early-stage OSCC,
and advanced-stage OSCC samples (Figures 1 and S2), suggesting
their involvement in disease progression. Interestingly, the amplifi-
cation of 8q24.3 (harboring the candidate genes FBXL6, GPR172A,
PTP4A3) was found in almost 60% of the analyzed leukoplakia cases
and also in almost 70% of the tumors (Table S6).
We validated the 8q24.3 amplification by nuc ish using a disjoint
validation set of 108 leukoplakia and 185 OSCC samples (Figure 2A
and Table 1). The 8q24.3 locus-specific probe and a centromere 8 probe
hybridized to their target loci and showed no cross reactivity (Figure 2A).
The percentage of cells with 8q24.3 amplification increased as disease
progressed from leukoplakia to OSCC, and the amplification was
associated with disease progression (P b0.001) (Figure 3A). Almost
95% of the advanced-stage OSCC samples used for validation had a
weak amplification of 8q24.3 in more than 40% of the tumor cells
(Figure 3B). Moreover, this amplification was significantly associated
with tumor grade (P =.046) and lymph node metastasis (P =. 0.007).
The strong amplification of 8q24.3 in leukoplakia and tumors was only
present in 5–20% of cells (Figure 3C). Our validation results confirm
that 8q24.3 amplification is an important early event associated with
OSCC progression.
CNAs associated with clinical outcome. Chromosomal alterations
were also analyzed for their associations with clinicopathologic
parameters, including nodal status, grade, and survival.We identified
64 recurrent chromosomal alterations in lymph node metastasis-
negative OSCCs and 46 recurrent alterations in lymph node
metastasis-positive OSCCs (q-value b0.25, Figure S3). In addition,
we found 13 alterations unique to the primary tumors that
metastasized to the nodes (Figure S2C and D), including
amplifications of 8p23.1, 8q24.21 (harboring the candidate gene
MYC), 11q22.1 (MMPs, BIRC2, BIRC3), and deletions of 2q23.3,
3p26.3 (CHL1), 3p12.2, 4q21.3, 7q31.1, 8p23.2 (CSMD1), 9p12,
11q22.3 (ATM, H2AFX), as well as 18q12.1. We hypothesize that
these alterations are potential predictive biomarkers of lymph node
metastasis. According to previous studies, the amplification of
8q24.21 and the deletion of 3p26.3 are associated with metastasis,
invasion, and therapy resistance [20,21].
We found 25 CNAs associated with recurrence-free survival and 26
CNAs associated with disease specific survival (q-value b0.25, Table 2).
For example, the amplifications of 1p36.33, 11q13.3, 11q22.1 and
16p11.2 were associated with poor clinical outcome, whereas the
Table 2. Univariate Cox Proportional Hazards Regression Analysis of Single Predictors for
Recurrence-Free and Disease Specific Survival.
Cytoband Alteration Disease Specific Survival Recurrence-Free Survival
BH Corrected
P-Value
CPH Coef. BH Corrected
P-Value
CPH Coef.
1p36.33* Amplification 0.0327 1.0292 0.013 0.9185
1q23.2 Amplification 0.0269 0.8763 0.0934 0.574
3q27.2 Amplification 0.2467 0.436 0.2171 0.3823
11q13.3 Amplification 0.1232 0.4237 0.2142 0.2804
16p13.3 Amplification 0.0655 0.6641 0.0658 0.5375
16p11.2 Amplification 0.0497 0.8665 0.0549 0.6726
16q12.2 Amplification 0.0607 0.6662 0.0308 0.6497
2p11.2 Deletion 0.0473 1.0051 0.0844 0.777
2q22.1 Deletion 0.0147 1.0214 0.0623 0.6329
2q34 Deletion 0.0644 0.7772 0.0281 0.745
3p14.2 Deletion 0.1976 0.5665 0.2202 0.4236
4q13.2 Deletion 0.0582 0.8036 0.1775 0.4836
4q22.1 Deletion 0.0998 0.7098 0.2113 0.4591
9p23 Deletion 0.0969 0.711 0.1339 0.5327
11q22.3 Deletion 0.0829 0.7902 0.099 0.6467
6p21.1 Amplification 0.2198 0.4606 - -
11q22.1 Amplification 0.1543 0.5204 - -
18p11.31 Amplification 0.2227 0.5128 - -
22q11.21 Amplification 0.1832 −0.6038 - -
1q31.3 Deletion 0.2371 0.5055 - -
3p11.1 Deletion 0.0809 0.7957 - -
4q13.2 Deletion 0.09 0.7457 - -
5p14.3 Deletion 0.112 0.7583 - -
7q31.1 Deletion 0.1624 0.598 - -
13q21.32 Deletion 0.2166 0.5221 - -
21q21.3 Deletion 0.1385 0.6243 - -
2q37.3 Amplification - - 0.2185 0.3978
5p15.33 Amplification - - 0.223 0.3284
11p15.5 Amplification - - 0.1793 0.4287
13q21.33 Amplification - - 0.2436 −0.7795
16q21 Amplification - - 0.1975 0.4048
19p13.3 Amplification - - 0.1465 0.3602
22q11.23 Amplification - - 0.1986 −0.4272
9p21.3 Deletion - - 0.2007 0.4494
14q11.2 Deletion - - 0.1116 0.5358
17p13.1 Deletion - - 0.0346 0.7927
BH: Benjamini-Hochberg multiple testing correction method; CPH coef.: Cox Proportional Hazard
coefficient. A positive regression coefficient means that the hazard is higher, thus the prognosis is worse;
* Targets selected for validation; − represents not applicable.
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amplification of 22q11.21 was associated with better survival.
Additionally, a poor clinical outcome was also associated with the
deletions of 2p11.2, 3p14.2, 4q13.2, 9p23 and 11q22.3. Kaplan–Meier
survival curves for 1p36.33 and 11q22.1 are shown in Figure 4A. We
validated the amplification of 1p36.33 by nuc ish (Figure 2B), and we
confirmed that the amplification of 1p36.33 is associated with poor
survival in an independent OSCC cohort (Figure 4B). Moreover, we
found a strong association between the amplification of 1p36.33 and
lymph node metastasis (P b .001).
Gene Expression and Integrative Analyses
Transcriptome-wide analysis was performed on 6 buccal mucosa
normal tissues, 15 leukoplakia, 27 early-stage OSCC, and 34
advanced-stage OSCC. Principal component analysis of 3805 differen-
tially expressed genes (log fold change of 2 and q-value ≤0.01) revealed
two separate clusters of normal and OSCC samples, while the
leukoplakia samples displayed changes overlapping with both these
groups (Figure S4).We identified 849 genes differentially expressed (395
up-regulated and 454 down-regulated) in leukoplakia, 1813 (805
Figure 4. Kaplan–Meier plots of disease specific patient survival for selected chromosomal alterations based on aCGH analysis (A, 1p36.33
and 11q22.1) and nuc ish validation experiments (B, 1p36.33). Survival inmonths (X axis) is plotted against the fractionof patients alive (Y axis).
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Figure 5. Heatmap of the top 20 differentially expressed genes in leukoplakia and OSCC. A) Differentially expressed genes in early-stage
OSCC (pink) and advanced-stage OSCC (magenta) when compared to normal (green). B) Differentially expressed genes in leukoplakia
(chartreuse) when compared to normal (green). Blue genes are up-regulated, while down-regulation is represented in red. All expression
values were scaled across samples.
Table 3. Associations Between DNA Copy Number Alterations and Differentially Expressed Transcripts in Leukoplakia and OSCC.
DE Genes in OSCC vs. NormalDE Genes in Leukoplakia vs. Normalq–ValueAlterationCytoband
1p36.33* Amplification 0.00037596 MXRA8GLTPD1, LOC148413
3q26.31 Amplification 0.01951 CAMK2N2, GOLIM4, KLHL6, CLDN11, EIF4G1, ECT2*,
GPR160, EIF5A2*, AP2M1
CHRD, ECT2*, EIF5A2*, KLHL6, NCEH1, GPR160
4q13.2 Amplification 0.00112
6p21.1 Amplification 0.11293 MDFI, VEGFA, C6orf132, PTK7, YIPF3YIPF3, NFKBIE
7p11.2 Amplification 3.31E–08 EGFR
7q11.23 Amplification 3.66E–07 SRRM3, SRCRB4D
7q22.1 Amplification 0.0012685 PCOLCEPCOLCE, GNB2
8q24.21 Amplification 0.0019006 FAM49B
8q24.3* Amplification 6.67E–07 FBXL6, GPR172A, ADCK5
9p24.1 Amplification 5.90E–05 CD274
9q34.3 Amplification 0.01951
11p15.5 Amplification 0.002778 SLC25A22, TMEM80, LSP1CHID1
11p11.2 Amplification 0.043015 PACSIN3, ARFGAP2
11q13.1 Amplification 9.71E–10 RNASEH2C
11q13.3 Amplification 1.09E–27 ANO1
12q13.2 Amplification 0.17411 MUCL1, HOXC9*, HOXC13*, ERBB3, ZNF385A, HOXC10, IKZF4 HOXC9*, MUCL1, HOXC13*, ERBB3, ITGA7, ITGA5, ZNF385A
14q11.2 Amplification 0.00033729 SALL2
14q32.33 Amplification 2.63E–05 INF2
16p11.2 Amplification 0.14231 CD19, PRSS36, IL27, SPN, SEZ6L2, FUS, CORO1A CD19, GDPD3, NUPR1, SPN, YPEL3, PRRT2
17p13.1 Amplification 0.17411 CLDN7, CLEC10A, ATP1B2, EFNB3, TMEM88CLDN7, CD68, TMEM88, PHF23
19p13.3 Amplification 4.12E–07 PPAP2C
20q11.22 Amplification 0.19131 SPAG4SPAG4, ERGIC3
22q11.21 Amplification 0.0012607 CLDN5, CDC45
22q11.23 Amplification 0.0049669 DERL3*, MMP11, C22orf43DERL3*, C22orf43
Xq28 Amplification 0.0063493 SSR4, FLNA, ARHGAP4SSR4, ATP6AP1, IRAK1
1q44 Deletion 2.09E–05 CNST
2q34 Deletion 0.00096669 IKZF2, SPAG16SPAG16
3p26.3 Deletion 0.0013306 CRBN, CAV3BHLHE40, C3orf32
3p21.1 Deletion 1.13E–05 CACNA2D3, SELK
3p14.2 Deletion 4.30E–20
4q13.2 Deletion 3.84E–07
9p21.3 Deletion 5.36E–11
10p11.21 Deletion 1.57E–05 PARD3
11q22.3 Deletion 0.042974 CARD18, POU2AF1, CTSC, ST3GAL4, THY1, TRIM29, EI24,
AMOTL1, PVRL1, ZC3H12C, CHEK1, DLAT
MMP10, MMP3, CRYAB, POU2AF1, EXPH5, FEZ1, CADM1,
CTSC, TMEM25, VWA5A, CHEK1, HSPB2, PANX1, AMICA1,
CARD17, ABCG4, ARHGAP32, UPK2, MPZL2, ETS1, FLI1,
SCN4B, TRIM29, ME3, C11orf52, C11orf54, THY1, FZD4,
OAF, PAFAH1B2, NLRX1, LOC283143, AMOTL1
17p13.1 Deletion 0.030986 ALOX12, CLDN7, VMO1, HS3ST3A1, CD68, GPR172B,
SLC25A11, C17orf59, TMEM88, ATP2A3, UBE2G1, PHF23
ALOX12, SPNS2, CLDN7, XAF1, GPR172B, GAS7, ALOX12B,
UBE2G1, CLEC10A, PMP22, USP43, ATP1B2, C17orf59,
EFNB3, AURKB, GGT6, TMEM88, ATP2A3
17q21.31 Deletion 2.56E–05 ETV4
21q21.3 Deletion 0.017484 JAM2, NRIP1, CYYR1ADAMTS5
DE: Differential expression; Red font indicates amplified loci or up-regulated genes, and Blue font indicates deleted loci or down-regulated genes. The majority of genes showed consistent
changes on both the DNA and the RNA levels, and are depicted here in black font (up-regulated genes in amplified regions and down-regulated genes in deleted regions). Few genes showed opposite
direction expression changes and are colored respectively (genes in blue font were down-regulated, but located in amplified regions, while genes in red font were up-regulated, but located in deleted regions).
* Targets selected for validation.
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Figure 6. qRT-PCR expression changes of the 10 target genes (2 down-regulated, 7 up-regulated and 1 unchanged) in normal, leukoplakia
and early and advanced-stage OSCC samples. The P-value (P) was calculated using the Spearman correlation test.
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up-regulated and 1008 down-regulated) in early-stage OSCC, and
1924 (798 up-regulated and 1056 down-regulated) in advanced-stage
OSCC (Figure S5). Up-regulation of NELL2, MFAP5, CA2, FLRT3,
HOXC9, CDH16, LRP12, PTPRZ1, TNNT1, WDR66, NEXN,
EGR2, HOXC13, E2F7, ECT2, EIF5A2 and down-regulation of
KRT19, DERL3, CD177, PSCA, FAM3B, ALOX12, MUC20,
CXCL13, KRT4, KRT3, CD19, KRT81, CLDN7, FCRL5,
POU2AF1, CD79A, TMPRSS2, MAL, TNFRSF17, FCN1, PNOC,
CXCL17, CEACAM1, FUT6, CLCA4, PITX1, DACT2, MEI1, GPX3
were observed in all three groups, revealing their role in disease
progression from pre-invasive to cancerous lesions. A higher number of
genes were dysregulated in OSCC compared to leukoplakia, including
CXCL10, MMP10, INHBA, GBP5, CXCL11, MMP3, FST, BATF2,
SPP1, SH2D5, CXCL9, IFIT3, SERPINE1, GALNT6, FOXL2,
PDPN, ITGA3, VEGFC, STAT1, LY6K, KLF7, SOX9 and CD274.
Among all the differentially expressed genes identified in this study, 61
have been previously reported to be involved in leukoplakia and 188 in
oral or head and neck cancers, including ECT2, INHBA, SERPINE1,
GBP5,MMP10,MMP3, LY6K, SPP1, PDL1, PTHLH, KRT4, KRT76
andMAL[10,22–26]. The novel oral cancer driving genes identified here
includeDERL3, EIF5A2, HOXC9, HOXC13, MFAP5, NELL2, CD274,
DHRS2, FST and GPX3. The top dysregulated genes in leukoplakia and
OSCC are represented in Figure 5 and listed in Table S7.
Integrative analysis of gene expression and CNAs. We integrated
the GE and CNA datasets to identify genes whose expression and copy
number status were correlated. We found 3q26.31, 6p21.1, 7p11.2,
8q24.21, 8q24.3, 9p24.1, 11q13.3, 12q13.2, 16q24.2 and 17p13.1 as
chromosomal hotspots for copy number-dependent gene overexpres-
sion, while 1q44, 2q34, 3p26.3, 3p21.1, 10p11.21, 11q22.3, 17p13.1
and 21q21.3 were identified as regions of copy number-dependent gene
down-regulation (Table 3). In particular, 3q26.31 and 12q13.2,
spanning the genes ECT2, EIF5A2, HOXC9, HOXC13 and MUCL1,
showed a strong correlation between copy number amplifications and
gene over-expression. The deletion of 11q22.33 was correlated with a
few genes with significant copy number-dependent underexpression,
including CRYAB, POU2AF1, EXPH5, MPZL2 and ARHGAP32.
The opposite direction of expression change (amplification of
down-regulated genes and deletion of up-regulated genes) was observed
for a few genes, including MMP3, MMP10, FEZ1, CTSC, CHEK1,
PANX1 and PAFAH1B2. Interestingly, 16p11.2, 17p13.1 and
22q11.23 were significantly amplified, however, the majority of the
genes located in these three regions were down-regulated, e.g., CD19,
GDPD3, NUPR1, SPN, CLDN7 and DERL3 (Table 3), potentially a
consequence of epigenetic regulation.
Validation of dysregulated transcripts. To confirm the results of the
GE analysis, real-time qRT-PCR (TaqMan assays) was performed in 32
normal, 37 leukoplakia, and 138 OSCC samples. We selected 10 genes
for validation based on either novelty or on published studies
implicating these genes in OSCC development (Table S4): seven
up-regulated genesDVL1, EIF5A2, FUS,HOXC9, INHBA, LY6K, and
MFAP5, two down-regulated genes DERL3 and MAL, and the
unchanged gene SLC4A1AP, along with RNA18S5 as endogenous
control. All the validation targets that were found to be differentially
expressed in the GE analysis were confirmed to display significant
differences in expression between normal, leukoplakia, and tumors
(Figure 6), and no significant difference was found in the expression of
the unchanged gene SLC4A1AP. Specifically, HOXC9, MFAP5, and
INHBA showed very high expression changes in leukoplakia, early
and advanced tumors versus normal (Pb.01), while EIF5A2 and LY6KTa
bl
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were significantly overexpressed only in early and advanced-stage
OSCCs (Pb.0001 and P =.03, respectively). The log2 fold change in
expression of DVL1 and FUS was approximately 1 across the three
groups, consistent with the microarray data.
We analyzed the associations between the validated target genes and
clinicopathologic parameters (Table 4).Most targets (EIF5A2, HOXC9,
MFAP5, LY6K, INHBA and DVL1) showed a positive correlation
between their expression changes and OSCC progression from
pre-invasive lesions to cancer. The expressions of DERL3 and MAL,
which are down-regulated, were negatively correlated with disease
progression. EIF5A2, HOXC9, INHBA, and MFAP5 were associated
with disease advancement from early-stage OSCC to advanced-stage
OSCC, and EIF5A2, HOXC9, INHBA, FUS and DVL1 were
significantly associated with lymphnodemetastasis. IHCwas performed
to validate the protein overexpression of EIF5A2, ECT2, HOXC9,
HOXC13, MFAP5, and NELL2. IHC analysis revealed strong protein
expression of all the six targets in leukoplakia (n = 108) andOSCC (n =
185) versus normal (n = 77) (Figure 7). Further analyses reinforced the
associations of these markers with disease progression, except NELL2
(Figure S6 and Table S8).
Pathway Analyses
To interpret the association of dysregulated genes with biological
processes, we used the PANTHER (Protein ANalysis THrough
Evolutionary Relationships) classification system [27,28] (Figure S7).
Both leukoplakia and OSCC samples shared a large number of
Figure 7. IHC analysis for target validation in normal, leukoplakia, and OSCC samples. NELL2 showed cytoplasmic staining, EIF5A2, ECT2,
HOXC9, HOXC13 showed cytoplasmic and nuclear expression, while MFAP5 was localized predominantly into the matrix. Respective
isotype controls for all the cases had no staining (images not shown). The rightmost panel shows differential localization of each marker.
The magnification was 100X for the leftmost three panels, and 200X for the rightmost panel.
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dysregulated processes. However, we identified a higher number of
OSCC-related genes as part of dysregulated pathways as compared
to genes related to pre-invasive lesions. Among them, we note genes
associated with apoptotic processes (FADD, BAX, BAK1, CASP7,
INHBA,BIRC5), developmental processes (HOXC9,HOXC13,NELL2,
CD274, ETS, STAT1), biological regulation (BATF, HOXC9, TERC),
and metabolic processes (RAD51, HOXC13, E2F1, HOXB6, CDK1).
The top representative biological processes significantly altered in
leukoplakia and OSCC are listed in Table 5.
Discussion
We have presented the first comprehensive analysis of genomic and
transcriptomic profiles of a large set of tobacco-associated, HPV-negative
gingivobuccal leukoplakia andOSCC patients from India. Our main goals
were threefold: 1) to identify novel driver events associated with the
transformation of pre-invasive lesions to high risk malignant OSCCs, as
well as with patient survival; 2) to identify unique driver alterations found in
primary tumors with lymph nodemetastasis; and 3) to identify driver genes
with correlated CNA and gene expression profiles. Therefore, our study
contributes to a genetic progressionmodel of oral carcinogenesis (Figure 8).
The CNA landscape of gingivobuccal cancers is dominated by
amplifications of the chromosomal regions 1p36.33, 3q26.31, 6p21.32,
7p11.2, 8q24.21, 8q24.3, 9q34.3, 11q13.1, 11q13.3, 11q22.1,
12q13.2, 16p11.2, and deletions of 3p21.1, 3p14.2, 4q21.3, 8p23.2,
8p11.22, 9p23, 9p21.3, 17p13.1. The amplifications of 3q, 7p, 8q, 9q,
11q, and 12q, as well as the deletions of 3p, 4q, 8p, and 9p were reported
at least three times among 12 aCGH studies on primary OSCC tumors
[19], with amplifications of 3q26, 11q13 and 11q22.2 being the most
reported CNAs in advanced-stage OSCCs [9,29,30]. An extensive
review by Gollin outlines established associations of most of these
alterations in HNSCC [31]. In our data, at the whole-arm level, the
amplification of 8q is the most common amplification associated with
OSCC progression. At the sub-band level, the amplification of 8q24.3
was observed in 58% of the leukoplakia samples, as well as in 69%of the
OSCC samples, while the region 8q24.21 was amplified in 55% of the
OSCC samples. PTK2, LY6K, and MYC are prominent candidate
oncogenes on 8q [10,32–34]. In addition, we observed deletions of
multiple regions on 3p (3p26.3, 3p22.3, 3p21.1, 3p14.2, 3p11.1) and
8p (8p23.2, 8p23.1, 8p22, 8p11.22) with high frequency (N52% in
OSCCs), in line with literature reports in oral pre-invasive lesions
[35,36]. These alterations can therefore be considered as important
events associated with OSCC progression [36].
We observed strong correlations between gene expression and
amplifications at 3q26.31 (including the genes ECT2, EIF5A2, KLHL6,
GPR160) and 12q13.2 (HOXC9, HOXC13, ERBB3, MUCL1) in both
Table 5. Representative Biological Processes Significantly Altered in Leukoplakia and OSCC.
GO:BP:ID P-Value Odds ratio Count Size Biological process
Leukoplakia
GO:0044691 6.57E-05 433.0789474 2 3 tooth eruption
GO:0035116 0.000373976 24.34222222 3 30 embryonic hindlimbmorphogenesis
GO:0021983 0.000879749 17.75243243 3 40 pituitary gland development
GO:0030199 0.000879749 17.75243243 3 40 collagen fibril organization
GO:0001568 0.001192229 3.794054527 9 556 blood vessel development
GO:0071230 0.001591348 14.27130435 3 49 cellular response to amino acid
stimulus
GO:0043206 0.001656565 39.34688995 2 13 extracellular fibril organization
GO:0040012 0.002562823 11.97495573 3 62 regulation of locomotion
GO:0044259 0.002720644 7.421757892 4 123 multicellular organismal
macromolecule metabolic process
GO:0009888 0.002854111 2.692398599 13 1260 tissue development
OSCC
GO:0008544 1.03E-09 5.089295677 24 307 epidermis development
GO:2,000,145 1.90E-08 3.377582317 33 628 regulation of cell motility
GO:0051674 3.78E-07 2.447114154 47 1237 localization of cell
GO:0051272 4.34E-07 3.851913001 22 361 positive regulation of cellular
component movement
GO:0040017 6.57E-07 3.750171556 22 370 positive regulation of locomotion
GO:0043207 1.47E-06 2.622472611 36 869 response to external biotic stimulus
GO:0060337 2.07E-06 7.805019305 10 84 type I interferon signaling pathway
GO:0034340 2.31E-06 7.70047619 10 85 response to type I interferon
GO:0018149 5.56E-06 9.573286052 8 56 peptide cross-linking
GO:0032496 8.14E-06 5.32031185 12 145 response to lipopolysaccharide
The top 10 dysregulated pathways (ordered by corrected P-value in Leukoplakia and OSCC), as
identified by the Bioconductor package GOStats.
Figure 8. Summary of the predictive genomic and transcriptomic signatures associated with gingivobuccal cancer progression from
pre-invasive lesions (leukoplakia) to cancer and lymph nodemetastasis. (*) represents alterations associated with disease specific survival
in OSCC patients. Amp: Amplification (red); Del: Deletion (blue); Up: genes up-regulated (red), Down: genes down-regulated (blue).
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leukoplakia and OSCC. Amplifications at 9p24.1 (CD274), 11q13.3
(ANO1), and 7p11.2 (EGFR) were only identified in OSCCs, indicating
their role in disease advancement, rather than their appearance at
pre-invasive stages. Additionally,CD274 and its ligand PD1 are important
targets of immunotherapy in various cancers, including OSCC [37–40].
A second hotspot for CNA-dependent gene over-expression was
observed on 3q26.31, with ECT2 and the oncogene EIF5A2
over-expressed. Overexpression of EIF5A2 has not been previously
reported in leukoplakia or OSCC, even though it has been proposed
as a prognosis biomarker and potential therapeutic target for various
other human tumors [41–44]. ECT2 has been previously found to be
overexpressed in oral cancers [22], and also be involved in metastasis
and angiogenesis of solid tumors [43,45–47].
A third interval of interest for amplifications and gene overexpression
is 12q13.2, comprising of HOXC9 and HOXC13, genes associated
with disease progression in OSCC. TheHOX transcriptional regulators
family is involved in pattern formation and organogenesis during
embryo development [48] and potentially in the maintenance and
regulation of cancer stem cells [49]. In particular, HOXC9 has been
linked with cell cycle exit and cell invasion in breast cancer and
neuroblastoma [48,50–52], and HOXC13 plays an important role in
maintaining skin homeostasis and in regulating the transcription of
cytokeratins genes [53,54]. Kasiri et al. [55] and Cantile et al. [56]
showed thatHOXC13 is a key player in tumor cell growth and viability
in various human cancers.
Pathare et al. [57] and Bhattacharya et al. [58] demonstrated that
specific CNAs are associated with lymph nodemetastasis. Here, themost
frequent such alteration, specific to the lymph node metastatic tumors,
was the amplified region 8q24.21 (57%), which includes the geneMYC,
whose over-expression is postulated to activate various hallmarks of
cancer, such as metastasis, invasion, and therapy resistance [20,59]. A
highly recurrent deletion identified was 3p26.3 (57%), including the
gene CHL1, alteration previously reported as a predictor of survival and
lymph node metastasis in OSCC, along with loss of 3p14.2 (FHIT)
[21,60]. The deletion of 8p23.2 was the most frequent in our study
(68%). Genes in this region have been reported to be involved in lung,
head and neck, breast, and skin cancers [61], but further studies are
required to delineate its functional role in OSCC progression.
We separately analyzed early-stage and advanced-stage OSCCs to
identify distinguishable CNAs with respect to recurrence and survival.
For the first time, we report a recurrent amplification on 1p36.33 as
significantly associated with clinical outcomes. Literature evidence
supports that genes located on 1p, including JUN (1p32–31), TP73
(1p36.3), CASP9 (1p36.21), and NRAS (1p13.2), are important in
the initiation and progression of several cancer types [62,63]. Genes
of interest on the 1p36.33 amplicon include MXRA8 and DVL1.
Here, we report the copy number dependent up-regulation of
MXRA8, previously shown to function in tumor stroma by aiding the
recovery of angiogenesis in capillaries [64,65]. DVL1 belongs to the
Wnt signaling pathway known to be involved in growth, progression,
and metastasis of various cancer types [66].
Additionally, we report copy number independent up-regulation of
INHBA, MFAP5 andNELL2 in both leukoplakia and OSCC samples.
MFAP5 is a secretory stromal protein overexpressed in leukoplakia and
OSCC, possibly playing a role in malignant transformation and as a
potential serum biomarker of cancer progression. Reports on ovarian
cancer suggest that MFAP5 promotes tumor cell survival and
angiogenesis through α5β3 integrin-mediated signaling [67–69]. We
identified few genes in copy number-altered regions that had a
significant expression change in the direction opposite to what would be
expected (e.g., a down-regulated gene in an amplified region), possibly
following epigenetic regulation. One example is the down-regulation of
DERL3, located at the 22q11.23 amplicon. Further studies are needed
to confirm the significance of the DERL3 in oral tumorigenesis and to
understand its gene regulation.
In sum, our study identifies CNAs and gene expression changes
related to oral cancer progression. Alterations shared between leukoplakia
and OSCC can be considered as important early events that are essential
for initial cell transformation and progression. Integrative analysis of
CNA and gene expression allows us to identify various novel drivers in
oral cancer pathogenesis.
Supplementary data to this article can be found online at http://dx.doi.
org/10.1016/j.tranon.2017.03.008.
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